Shukra Pharmaceuticals Quarterly Results
Shukra Pharmaceuticals quarterly results. In Sept 2026, Shukra Pharmaceuticals (SHUKRAPHAR) reported revenue ₹45 Cr and net profit ₹13 Cr — revenue +462.5% YoY. View SHUKRAPHAR yearly price range for the annual high/low range and current price position.
SHUKRAPHAR Quarterly Results — Revenue, Profit & EPS Highlights
Shukra Pharmaceuticals latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore Shukra Pharmaceuticals share price performance to track price trends across different timeframes.
- Revenue of ₹45 Cr in Sept 2026 (+542.9% vs Mar 2026, +462.5% vs Sept 2025)
- Net Profit of ₹13 Cr in Sept 2026 (+750.0% vs Mar 2026, +550.0% vs Sept 2025)
- EBITDA of ₹19 Cr in Sept 2026 (+850.0% vs Mar 2026)
- Operating Margin of 42.0% in Sept 2026 (+31.0pp vs Mar 2026)
- Earnings Per Share of ₹0.29 in Sept 2026 (+825.0% vs Mar 2026)
Shukra Pharmaceuticals Quarterly Results — Revenue, EBITDA, Net Profit & EPS
SHUKRAPHAR quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2026 | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 45 | 7 | 24 | 8 | 15 | 542.9% | 462.5% |
| Net Profit (₹ Cr) | 13 | -2 | 13 | 2 | 5 | - | - |
| EBITDA (₹ Cr) | 19 | 2 | 20 | 1 | 9 | - | - |
| EPS (₹) | 0.29 | -0.04 | 0.30 | 0.05 | 0.12 | - | - |
| Operating Margin (%) | 42.0% | 11.0% | 81.0% | -7.0% | 55.0% | - | - |
SHUKRAPHAR Share Price Trend — 1-Year Movement Across Quarterly Results
Shukra Pharmaceuticals 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit SHUKRAPHAR share price.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
SHUKRAPHAR vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Shukra Pharmaceuticals latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2026 |
₹451,074.97 Cr | 1900.0 | 16,617 | 1,995 | +10.6% | - | 12.0% | 228.9 |
|
Divis Laboratories
Sept 2026 |
₹294,139.19 Cr | 11178.0 | 3,770 | 1,127 | +26.3% | - | 29.9% | 263.1 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4611.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 400.6 |
|
Apollo Hospitals
Sept 2026 |
₹126,832.45 Cr | 8738.0 | 7,673 | 660 | +15.2% | - | 8.6% | 199.4 |
|
Laurus Labs
Sept 2026 |
₹125,946.78 Cr | 2306.0 | 2,219 | 436 | +21.7% | - | 19.6% | 282.3 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores